The prevalence of allergic diseases, specially respiratory allergic diseases such as allergic rhinitis and asthma, has been increasing worldwide for the last 2 decades \[[@B1], [@B2]\]. Although avoidance of the responsible allergen, anti-inflammatory, and symptomatic treatment modalities has shown great efficacy in the treatment of allergic respiratory disorders, cessation of pharmacotherapy usually results in recurrence of signs and symptoms, with a demand to restart the treatment.

Currently, allergen-specific immunotherapy (SIT) is the only available curative choice with the capacity of altering the natural course of allergy \[[@B3], [@B4]\]. Although SIT by the subcutaneous route has been extensively used and has shown marked efficacy since its discovery, it was associated with uncommon, but severe or even fatal, systemic reactions \[[@B5]\]. Consequently, alternative, noninjectve allergen delivery routes have been proposed, and allergen delivery through mucosal surfaces was suggested as a possible mechanism for the induction of mucosal tolerance to allergens \[[@B5], [@B6]\]. Local mucosal routes such as oral, nasal, bronchial, and sublingual were investigated since then, and controlled trials failed to demonstrate satisfactory clinical efficacy and/or safety of oral, nasal, and bronchial allergen application; therefore those routes have been abandoned \[[@B7]--[@B11]\]. Meanwhile, the efficacy and safety of SIT via the sublingual route was well documented by a number of controlled trials both in children and adults with asthma and/or rhinitis \[[@B12], [@B13]\]. Since then, sublingual immunotherapy (SLIT) in the liquid drop formulation has been tested in a large number of double-blinded, placebo-controlled studies, and those studies were included in Cochrane meta-analyses \[[@B14]--[@B16]\] demonstrating efficacy both in children and adults with allergic rhinitis or asthma sensitized to house dust mite or various pollens. Thereafter, orodispersible grass-pollen tablets were developed and recent well-designed, well-powered, double-blinded, placebo-controlled studies demonstrated efficacy and safety of tablet formulation \[[@B17]--[@B20]\].

Some of those studies improved our understanding of the underlying immunological mechanisms in addition to the proven safety and efficacy. Recent studies demonstrated that SLIT exerts its immune-suppressive effect through the induction of Treg cytokines such as IL-10 and TGF-beta \[[@B21], [@B22]\]. This effect starts on the uptake of allergen by oral mucosal Langerhans cells through high-affinity IgE receptors \[[@B6]\]. More recent studies demonstrated increase in expression of Foxp3+ cells in the sublingual mucosa, which was accompanied by the systemic immunologic response during SLIT \[[@B23]\].

Hereby in this issue, data on clinical implications, efficacy, compliance, monitorization of delivery, and immunological mechanisms of allergen SIT delivered by the mucosal-mainly sublingual route will be presented.
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